Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Retrospective and prospective validation of a 33-gene signature to predict recurrence of lung cancer after surgery.


ABSTRACT: We developed a 33-gene signature that is strongly correlated to the time to recurrence in non-small cell lung cancer (NSCLC). The signature was validated retrospectively in 5 cohorts of 972 NSCLC patients and in one prospective study of 111 NSCLC Stage IA patients. In all cohorts, and all stages of the disease, the signature identified a rare, aggressive tumor type that had a high proportion of recurrence after surgery and a median survival of 35 months (95% C.I.: 19-58). This tumor type forms a separate cluster in an analysis of the expression of the 33 genes in patient tumors. The signature is associated with cellular processes required by rapidly growing and spreading tumors: cell migration and invasion, vascularization, and response to hypoxia. The signature also identifies patients with good prognosis (median survival 114 months, (95% C.I.: 85-160), and intermediate prognosis (median survival 61 months (95% C. I.: 50-73). The signature is quite robust and works on tumor samples archived in RNAlater, Tissue-Tek, or formalin-fixed and paraffin embedded. 156 samples -------------------------------- *** Submitter has not provided information such as time to recurrence. Thus, the data is incomplete.

ORGANISM(S): Homo sapiens

SUBMITTER: Anker Hansen 

PROVIDER: E-GEOD-77803 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

Similar Datasets

2016-02-11 | GSE77803 | GEO
2022-11-02 | GSE210287 | GEO
2011-11-26 | E-GEOD-25727 | biostudies-arrayexpress
2018-02-18 | GSE95246 | GEO
2018-09-11 | PXD009254 | Pride
2011-11-26 | GSE25727 | GEO
2006-06-07 | GSE4882 | GEO
| PRJNA156819 | ENA
2014-01-24 | GSE54328 | GEO
2012-07-01 | GSE38057 | GEO